Reporting to: VP Pharmacovigilance
Location London, UK / Hybrid
Orchard Therapeutics is a global biotechnology gene therapy company dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative cell and gene therapies. Orchard has its global headquarters in London and is a wholly owned subsidiary of Kyowa Kirin, a Japan-based Global Specialty Pharmaceutical Company.
The Senior Manager, PV Operations is a key operational leader responsible for the execution and management of global pharmacovigilance operations. This role on a day to day basis ensures the seamless delivery of case management, regulatory reporting, and operational compliance across clinical and post-marketing portfolios.
This role serves as the primary operational interface for PV vendors and cross‑functional study teams. The Senior Manager, PV Operations is an emerging expert who translates the functional strategy into actionable operational plans, manages complex technical issues with limited guidance, and ensures that the "hands‑on" elements of the PV system are robust, scalable, and inspection‑ready.
Key Elements and Responsibilities
Requirements
Education, Experience & Knowledge
Education
Experience
Desirable
Skills & Abilities
· Self-motivated, with initiative and ability to take ownership of, and follow through with, specific tasks
· Working knowledge of available information sources and ability to navigate multiple channels to secure required information
· Works effectively with cross-functional teams to address complex issues and recommend actions with potentially significance impact
· Effective time management and organization skills
· Ability to multi-task and shift priorities quickly while working under tight deadlines
· Excellent verbal and written communication skills
· Strong PC experience and demonstrated proficiency in MS Office (Outlook, Word, Excel and Powerpoint)

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment.
Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.
For more information, please visit https://www.orchard-tx.com/.